Summary

As additional treatments have been approved for rheumatoid arthritis (RA), researchers have used clinical trial data to analyze the cost effectiveness of these new drugs. Since 1998, more than 30 cost-effectiveness analyses (CEAs) have been conducted, with highly variable results. This article presents the CEA results of patient-level data from the Treatment of Early Aggressive Rheumatoid Arthritis trial [TEAR; NCT00259610], a large, randomized, double-blind clinical study.